BridgeBio Pharma, Inc. (BBIO)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous Close | 27.74 |
| Open | 28.45 |
| Bid | 27.79 x 200 |
| Ask | 27.84 x 200 |
| Day's Range | 27.18 - 28.78 |
| 52 Week Range | 12.75 - 44.32 |
| Volume | |
| Avg. Volume | 1,693,645 |
| Market Cap | 5.208B |
| Beta (5Y Monthly) | 1.03 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.23 |
| Earnings Date | Aug 01, 2024 - Aug 05, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 49.83 |
Simply Wall St.What You Need To Know About The BridgeBio Pharma, Inc. (NASDAQ:BBIO) Analyst Downgrade Today
The latest analyst coverage could presage a bad day for BridgeBio Pharma, Inc. ( NASDAQ:BBIO ), with the analysts...
Simply Wall St.BridgeBio Pharma First Quarter 2024 Earnings: Beats Expectations
BridgeBio Pharma ( NASDAQ:BBIO ) First Quarter 2024 Results Key Financial Results Revenue: US$211.1m (up by US$209.3m...
GlobeNewswireBridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update
- Presented cardiac magnetic resonance (CMR) imaging evidence consistent with clinical improvement observed in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in the ATTRibute-CM Phase 3 study of acoramidis at the American College of Cardiology Annual Scientific Sessions; additional detailed results from ATTRibute-CM are planned for presentation at 2024 medical meetings, including four abstracts accepted for the European Society of Cardiology Heart Failure conference and eleven abst
© 2024 Yahoo. All rights reserved.